The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

BACKGROUND AND AIMS: We aimed to validate the predictive factors for tumor response and the prognostic impact of conversion therapy aimed at cancer‐ and drug‐free states in patients with unresectable hepatocellular carcinoma (u‐HCC) undergoing atezolizumab plus bevacizumab (Atez/Bev) therapy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimose, Shigeo, Iwamoto, Hideki, Shirono, Tomotake, Tanaka, Masatoshi, Niizeki, Takashi, Kajiwara, Masahiko, Itano, Satoshi, Yano, Yoichi, Matsugaki, Satoru, Moriyama, Etsuko, Noda, Yu, Nakano, Masahito, Kuromatsu, Ryoko, Koga, Hironori, Kawaguchi, Takumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278513/
https://www.ncbi.nlm.nih.gov/pubmed/37062077
http://dx.doi.org/10.1002/cam4.5931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278513/
https://www.ncbi.nlm.nih.gov/pubmed/37062077
http://dx.doi.org/10.1002/cam4.5931

Ejemplares similares